+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-melanoma Skin Cancer - Global Market Trajectory & Analytics

  • ID: 5309815
  • Report
  • April 2021
  • Region: Global
  • 175 pages
  • Global Industry Analysts, Inc
1 of 2
Global Non-melanoma Skin Cancer Market to Reach $682.4 Million by 2027

Amid the COVID-19 crisis, the global market for Non-melanoma Skin Cancer estimated at US$499.8 Million in the year 2020, is projected to reach a revised size of US$682.4 Million by 2027, growing at a CAGR of 4.5% over the period 2020-2027. Basal Cell Carcinoma (BCC), one of the segments analyzed in the report, is projected to record 4.4% CAGR and reach US$442.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Squamous Cell Carcinoma (SCC) segment is readjusted to a revised 4.9% CAGR for the next 7-year period.



The U.S. Market is Estimated at $147.2 Million, While China is Forecast to Grow at 4.3% CAGR

The Non-melanoma Skin Cancer market in the U.S. is estimated at US$147.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$120.9 Million by the year 2027 trailing a CAGR of 4.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Select Competitors (Total 46 Featured):
  • Accuray, Inc.
  • Almirall S.A.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • iCAD, Inc.
  • Ion Beam Applications SA
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Sensus Healthcare
  • Sun Pharmaceutical Industries Ltd.
  • Varian Medical Systems, Inc.
Note: Product cover images may vary from those shown
2 of 2
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Non-melanoma Skin Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Non-melanoma Skin Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Non-melanoma Skin Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Basal Cell Carcinoma (BCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Basal Cell Carcinoma (BCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Basal Cell Carcinoma (BCC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Squamous Cell Carcinoma (SCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Squamous Cell Carcinoma (SCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Squamous Cell Carcinoma (SCC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 16: USA Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 17: USA Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: USA 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 19: USA Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: USA Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: USA 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • CANADA
  • Table 22: Canada Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 23: Canada Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: Canada 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 25: Canada Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: Canada Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: Canada 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 28: Japan Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 29: Japan Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: Japan 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 31: Japan Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Japan Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: Japan 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • CHINA
  • Table 34: China Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: China Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: China 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 37: China Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: China Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: China 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 40: Europe Current & Future Analysis for Non-melanoma Skin Cancer by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 41: Europe Historic Review for Non-melanoma Skin Cancer by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: Europe 15-Year Perspective for Non-melanoma Skin Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 43: Europe Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: Europe Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: Europe 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 46: Europe Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 47: Europe Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: Europe 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 49: France Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: France Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 51: France 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 52: France Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 53: France Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 54: France 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 55: Germany Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 56: Germany Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 57: Germany 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 58: Germany Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 59: Germany Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 60: Germany 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • ITALY
  • Table 61: Italy Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 62: Italy Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 63: Italy 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 64: Italy Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 65: Italy Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 66: Italy 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 67: UK Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 68: UK Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 69: UK 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 70: UK Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 71: UK Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 72: UK 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 73: Rest of Europe Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 74: Rest of Europe Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 75: Rest of Europe 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 76: Rest of Europe Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 77: Rest of Europe Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 78: Rest of Europe 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 79: Asia-Pacific Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 80: Asia-Pacific Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 81: Asia-Pacific 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 82: Asia-Pacific Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 83: Asia-Pacific Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 84: Asia-Pacific 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 85: Rest of World Current & Future Analysis for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 86: Rest of World Historic Review for Non-melanoma Skin Cancer by Segment - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 87: Rest of World 15-Year Perspective for Non-melanoma Skin Cancer by Segment - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) for the Years 2012, 2020 & 2027
  • Table 88: Rest of World Current & Future Analysis for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 89: Rest of World Historic Review for Non-melanoma Skin Cancer by Treatment - Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 90: Rest of World 15-Year Perspective for Non-melanoma Skin Cancer by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatments for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 46
Note: Product cover images may vary from those shown
Adroll
adroll